{arrow_up} Back to top

Risk Minimisation Materials

Search by company, common medicine name, or title of Risk Minimisation Material

Sarclisa

SANOFI

{pdf_link}

Sarclisa HCP Brochure

{healthcare_pro_orange} For Healthcare Professionals

This brochure contains important information for HCPs & blood banks concerning the appropriate measures to manage isatuximab interference and avoid possible resulting adverse clinical consequences and to inform that isatuximab may interfere with routine blood compatibility tests with potential false positive reactions in the indirect antiglobulin test (indirect Coombs test). For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected].


{pdf_link}

Sarclisa Patient Alert Card

This patient alert card contains important safety information that you need to be aware of before, during, and after treatment with SARCLISA. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected].


Sialanar

Proveca Limited

{pdf_link}

Checklist for Healthcare Professionals

{healthcare_pro_orange} For Healthcare Professionals

These educational materials focus on the provision of advice for the recognition of anticholinergic effects that can be associated with glycopyrronium bromide containing products and how best to manage specific events.


{pdf_link}

Healthcare Professional Checklist Labels

{healthcare_pro_orange} For Healthcare Professionals

This is a sheet of checklist labels to help record anticholinergic effects in a patient’s notes.


{pdf_link}

Reminder Card for Caregivers

These educational materials focus on the provision of advice for the recognition of anticholinergic effects that can be associated with glycopyrronium bromide containing products and how best to manage specific events.


Siklos

Masters Pharmaceuticals Ltd

{pdf_link}

Dosing Sheet

The dosing sheet provides information, and a place to keep a record of the patient's dosing for monitoring purposes. This can be viewed by both patients and physicians.


{pdf_link}

Patient's Guide to Siklos

This Siklos Patient Guide contains important information about your treatment, or your child's treatment including advice on preparation and administration of your medicine, disease symptoms, and side effects.


{pdf_link}

Physicians Guide to Siklos

{healthcare_pro_orange} For Healthcare Professionals

This Physician Guide for Siklos contains important recommendations for patient monitoring, dosage adjustments, and the management of serious adverse effects.


Sildenafil

Crescent Pharma Ltd

{pdf_link}

Essential Information For The Supply Of Zamantos 50mg film-coated tablets

{healthcare_pro_orange} For Healthcare Professionals

Essential information for supplier


{pdf_link}

Pharmacy Checklist for Zamantos 50mg film-coated tablets'

{healthcare_pro_orange} For Healthcare Professionals

Pharmacy checklist


Simponi

Merck Sharp & Dohme (UK) Limited

{pdf_link}

Patient Reminder Card

This risk minimisation material is a condition of the marketing authorisation. This card should be provided to patients receiving treatment with golimumab. It gives important safety information for the patient and allow important details of their treatment to be recorded


Skilarence

Almirall Limited

{pdf_link}

Healthcare Professional Guideline - Important safety information for Skilarence (dimethyl fumarate)

{healthcare_pro_orange} For Healthcare Professionals

This guideline is intended to inform HCPs about the risk of serious infections, mainly opportunistic infections such as progressive multifocal leukoencephalopathy (PML), associated with the use of Skilarence and to provide guidance on how to minimise and manage this risk through appropriate monitoring of lymphocyte and leukocyte count abnormalities.


Sodium oxybate

AS Kalceks

{pdf_link}

Sodium Oxybate 500 mg/ml oral solution, AS Kalceks, Educational Materials, Treatment Initiation and Follow-Up Visit Form

{healthcare_pro_orange} For Healthcare Professionals

- Important risk minimisation information for Healthcare Professionals: Treatment Initiation and Follow-Up Visit Form


Aristo Pharma Limited

{pdf_link}

How to take Sodium oxybate 500 mg/ml oral solution Brochure

Important risk minimisation information for Patients: How to take Sodium oxybate 500 mg/ml oral solution Brochure


{pdf_link}

Sodium Oxybate 500 mg/ml Oral Solution Frequently Asked Questions (FAQ) Information Sheet

{healthcare_pro_orange} For Healthcare Professionals

Important risk minimisation information for Patients: Sodium oxybate 500 mg/ml oral solution Frequently Asked Questions (FAQ) Information Sheet


{pdf_link}

Sodium Oxybate 500 mg/ml oral solution Patient Alert Card

Important safety information for patients, physicians and pharmacists.


{pdf_link}

Sodium oxybate 500 mg/ml oral solution Treatment Initiation and Follow-Up Visit Form

{healthcare_pro_orange} For Healthcare Professionals

This treatment initiation form is essential to ensure the safe and effective use of Sodium oxybate 500 mg/ml oral solution and the appropriate management of the important risks.


Sodium valproate

Seacross Pharmaceuticals Ltd

{pdf_link}

Guide for Healthcare professionals

{healthcare_pro_orange} For Healthcare Professionals

Educational material for Healthcare Professionals (HCPs) about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44(0) 2087315273 or email UK-Medicalinformation drug [email protected]


{pdf_link}

Patient Guide

Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44(0) 2087315273 or email UK-Medicalinformation [email protected]


Strandhaven Limited t/a Somex Pharma

{pdf_link}

Valproate - “White Box” Warning Labels

{healthcare_pro_orange} For Healthcare Professionals

FOR DISPENSARY USE ONLY. Warning Labels with Valproate Pregnancy Pictogram for Pharmacy to use with white box dispensing of these products. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]


{pdf_link}

Valproate - Healthcare professionals (HCPs) Guide Pregnancy prevention programme

{healthcare_pro_orange} For Healthcare Professionals

Educational material for Healthcare Professionals (HCPs) about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]


{pdf_link}

Valproate - Patient Card - Contraception and Pregnancy Prevention

Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]


{pdf_link}

Valproate Annual Risk Acknowledgement Form

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE. Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.


{pdf_link}

Valproate- Patient Guide- Pregnancy prevention programme

Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]


{pdf_link}

Valproate- Poster- Dispensary- Pregnancy Prevention Programme

{healthcare_pro_orange} For Healthcare Professionals

FOR DISPENSARY USE ONLY. Dispensary A4 Poster for Pharmacy with key information about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]


Wockhardt UK Ltd

{pdf_link}

Valproate - Annual Risk Acknowledgement Form

Patient Risk Acknowledgement Form


{pdf_link}

Valproate - HCP Guide

{healthcare_pro_orange} For Healthcare Professionals

Guide about use of valproate in pregnancy


{pdf_link}

Valproate - Patient Guide

Guide on use of of valproate during pregnancy


{pdf_link}

Valproate - Patient Reminder Card

Patient Reminder Card


{pdf_link}

Valproate - Poster

{healthcare_pro_orange} For Healthcare Professionals

Warning Poster


{pdf_link}

Valproate - Warning Labels

{healthcare_pro_orange} For Healthcare Professionals

Warning Labels for Cartons


Soliris

Alexion Pharma UK Ltd

{pdf_link}

Soliris Patient Safety Card

Important Safety Information for Patients Receiving Soliris® Show this card to any doctor involved in your care.


{pdf_link}

Soliris Patient/Parent Information

This guide is for adult patients and parents/legal guardians of a child who has been prescribed eculizumab. The guide provides you with important safety information that you must be aware of.


{pdf_link}

Soliris Physician's Guide

{healthcare_pro_orange} For Healthcare Professionals

The aim of this brochure is to educate and/or remind healthcare professionals about the selected prevention measures, detection, careful monitoring and/or proper management of selected safety concerns associated with eculizumab.


Spravato

Janssen-Cilag Ltd

{pdf_link}

Spravato (esketamine nasal spray): Healthcare Professional Guide

{healthcare_pro_orange} For Healthcare Professionals

This guide informs healthcare professionals about the four identified risks that may occur following Spravato treatment: transient dissociative states and perception disorders (dissociation), disturbances in consciousness (sedation), increased blood pressure and drug abuse. This guide describes the risks and explains how to minimise and manage them.


{pdf_link}

Spravato (esketamine nasal spray): Patient Guide

If you are being treated with Spravato, it is important that you understand the possible risks of taking this medicine. This guide will explain these risks and give you information about how you and your healthcare professional can reduce these risks. This guide does not replace the patient information leaflet that comes with your medicine and you should ensure you have read this prior to taking Spravato.


{pdf_link}

Spravato (esketamine nasal spray): Readiness-to-leave checklist for healthcare professionals

{healthcare_pro_orange} For Healthcare Professionals

The treating healthcare professional should use their clinical judgement and this checklist to decide whether the patient is ready to leave after Spravato administration.


Strensiq

Alexion Pharma UK Ltd

{pdf_link}

Strensiq Injection Guide for Parents/Caregivers

This Injection Guide is for the parents and caregivers of infant patients with paediatric-onset hypophosphatasia who would benefit from long-term enzyme replacement therapy and have been prescribed Strensiq®. The guide gives detailed instructions, with clear diagrams, on how to choose the injection site and how to carry out and record the injection of your infant or child. This guide is designed as a support document to the training given by your healthcare professional. Please contact your healthcare professional if you have any questions.


{pdf_link}

Strensiq Self-Injection Guide

This Self-Injection Guide is for patients with paediatric- onset hypophosphatasia who would benefit from long-term enzyme replacement therapy and have been prescribed Strensiq®. The guide gives detailed instructions, with clear diagrams, on how to choose your injection site and how to carry out and record your injection. This guide is designed as a support document to the training given by your healthcare professional. Please contact your healthcare professional if you have any questions.


Strontium ranelate

Aristo Pharma Limited

{pdf_link}

Stronium ranelate Aristo Patient Alert Card

{healthcare_pro_orange} For Healthcare Professionals

Contains important safety information including possible side effects that patients need to be aware of before and during treatment with Strontium ranelate.


{pdf_link}

Stronium ranelate Aristo Prescriber Guide and Checklist

{healthcare_pro_orange} For Healthcare Professionals

Important information on minimising cardiovascular risks, venous thromboembolism and skin reactions with strontium ranelate.


Suliqua

SANOFI

{pdf_link}

Suliqua- HCP Guide - Important information on dosing

{healthcare_pro_orange} For Healthcare Professionals

For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]


{pdf_link}

Suliqua- Patient Guide - Important information on dosing

For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]


Syonell

Lupin Healthcare (UK) Ltd

{pdf_link}

Valproate Annual Risk Acknowledgment Form

Valproate Annual Risk Acknowledgment Form


{pdf_link}

Valproate- Healthcare professionals (HCPs) Educational material Pregnancy prevention programme

{healthcare_pro_orange} For Healthcare Professionals

Educational material for healthcare professionals (HCPs) about the Pregnancy Prevention Programme


{pdf_link}

Valproate- Patient Card-Contraception and Pregnancy Prevention

Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme


{pdf_link}

Valproate- Patient Guide-Educational material- Pregnancy prevention programme

Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme


{pdf_link}

Valproate- Poster- Dispensary- Pregnancy Prevention Programme

{healthcare_pro_orange} For Healthcare Professionals

For pharmacy use only. Dispensary information about the Pregnancy Prevention Programme


{pdf_link}

Valproate- White Box Warning Labels

Valproate- White Box Warning Labels


You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?